Hepatitis C is endemic in this country.
I have same situtation like @Squrrel. You knows; after new update, valve made all old users prime account.
I have 2k hours since 2014. Rank: dmg.
In my first competitive game after new update, all of enemy team is "level 3 - no badge - 20 hours played accounts". (Loyality badge is void for me.) One of them took 45 kills from behind of door.
After this match, i gave myself a job. The overwatch inspector. In the past, we know some cheaters in prime. The prime ocean was not clear a little bit dirty. But now, the prime ocean = sewage...
This is very important for me. Because i want a clear game. 
Last 3 days i watched 17 suspect's demos. 
14 of them have spinbot(+aimbot+wall)
1 of them have just wall(he had really giod aim
1 of them have aim trigger.
1 clear.
The dirty percentage of ocean like %95... 
And all of my inspectation valve is giving me "thanks xp". But this is not the point. 
VALVE, you need much good anti-cheat system./r/RWBY Let's play a game. Vol 3 Ep 1 Nailed It

With all the predictions if whats coming for the season I have thought of a game for us to play. It's called Nailed It.

For each episode we predict things that will happen. They could be small like Yang will make a pun about how Vytal this tournament is for the world or huge like Ozpin will murder Yang for making a bad pun and the series will be dark from this point on. 

After the episode has aired in the discussion thread you can then link back to your predictions in this thread with a Nailed It.

Reminder, it is for single episodes only. Things may happen eventually,  but lets see who can predict whats JUST about to happen. Also please contain your links to the discussion thread to prevent spoilers for those that ~~weretoocheaptobesponsors~~ haven't watched it yet.Answer the following question: Is there a negative or positive tone to this product review? === Title: A pretty average collection of 80s'safe' hard-pop/soft rock Review: For the record, I didn't enjoy this CD much. All the songs featured are genuine hits, but notwithstanding their chart success, this is a pretty average collection of 80s'safe' hard-pop/soft rock. Only a few of the tracks grabbed my attention: "Rock This Town" by the Stray Cats (the first 45rpm I ever bought!), "Keep On Lovin' You" (REO Speedwagon) and Crowded House's, "Don't Dream It's Over" (which was a bigger hit when re-released in the 90s). The rest, unfortunately, are quite forgettable. This album is reasonably priced, and worth getting if you want to discover the 80s. But Amazon *does* sell better compilations than this.....Jon. Answer:
Answer:
NegativeI still don't like the idea that people are 'conditioned' to think that they should be outside the norm when they aren't because it's the complete opposite of what happens. Things are called 'the norm' because they're what's seen as 'default' and are pressured/enforced. The problem with norms is that when someone falls outside of the norm there's massive societal pressure to appeal to the norms. Not the other way around.  Societal norms create pointless pressure on those who do not fall under them, and Peterson is reinforcing those norms by claiming that people who don't fall under them actually should and are just wrong.

It just seems like he's completely backwards. It seems like his view is that norms are good because they allow people to follow them? I can't really think of a good way to word that. Whereas the "SJW" view is that norms are bad because they put pointless pressure on people to follow them where if everyone could just do their own thing without the pressure they'd be happier/healthier.Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

Background Currently biomarkers play an essential role in diagnosis, treatment, and management of cancer. In non-small cell lung cancer (NSCLC) determination of biomarkers such as ALK, EGFR, ROS1 or PD-L1 is mandatory for an adequate treatment decision. The aim of this study is to determine the clinical and economic impact of current anaplastic lymphoma kinase testing scenario in Spain. Methods A joint model, composed by decision-tree and Markov models, was developed to estimate the long-term health outcomes and costs of NSCLC patients, by comparing the current testing scenario for ALK in Spain vs a hypothetical no-testing. The current distribution of testing strategies for ALK determination and their sensitivity and specificity data were obtained from the literature. Treatment allocation based on the molecular testing result were defined by a panel of Spanish experts. To assess long-term effects of each treatment, 3-states Markov models were developed, where progression-free survival and overall survival curves were extrapolated using exponential models. Medical direct costs (expressed in €, 2019) were included. A lifetime horizon was used and a discount rate of 3% was applied for both costs and health effects. Several sensitivity analyses, both deterministic and probabilistic, were performed in order test the robustness of the analysis. Results We estimated a target population of 7628 NSCLC patients, including those with non-squamous histology and those with squamous carcinomas who were never smokers. Over the lifetime horizon, the current ALK testing scenario produced additional 5060 and 3906 life-years and quality-adjusted life-years (QALY), respectively, compared with the no-testing scenario. Total direct costs were increased up to € 51,319,053 for testing scenario. The incremental cost-effectiveness ratio was 10,142 €/QALY. The sensitivity analyses carried out confirmed the robustness of the base-case results, being the treatment allocation and the test accuracy (sensitivity and specificity data) the key drivers of the model. Conclusions ALK testing in advanced NSCLC patients, non-squamous and never-smoker squamous, provides more than 3000 QALYs in Spain over a lifetime horizon. Comparing this gain in health outcomes with the incremental costs, the resulting incremental cost-effectiveness ratio reinforces that testing non-squamous and never-smoker squamous NSCLC is a cost-effective strategy in Spain. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08407-1.


Background
Lung cancer is the leading cause of cancer death worldwide and was responsible for the highest number of deaths from cancer in Spain in 2018, with 22,133 deaths [1,2]. Non-small cell lung cancer (NSCLC) accounts for 85-90% of lung cancer cases [3]. NSCLC has various histological subtypes, of which adenocarcinoma is the most common. In this subtype of NSCLC, several oncogenic and actionable drivers have been described, such as rearrangement of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 5% of cases of NSCLC [4]. Other actionable mutations have been detected in patients with NSCLC which affect the epidermal growth factor receptor (EGFR), BRAF, ERBB2, MET and gene fusions involving ROS1, RET or NTRK1-3 [5]. About 70% of NSCLC patients have advanced disease at diagnosis, meaning they are not suitable for curative treatment [6]. The concept of personalized medicine came up with the identification of predictive biomarkers that enable the detection of patients who may obtain the greatest benefit with least associated toxicity from treatments such as chemotherapy or immunotherapy, or targeted therapy based on the individual tumor profile [7]. The detection of specific genomic alterations, such as ALK gene rearrangement in lung cancer patients, has evolved, leading to improved new detection techniques, and is currently considered indispensable in NSCLC for the prognostic evaluation, clinical decision-making and appropriate treatment [8]. Therefore, molecular genotyping at the diagnosis of advanced NSCLC is critical, since target identification is absolutely essential to allow access to therapies with the best efficacy and safety profile [9].
Currently, various methods allow the detection of ALK rearrangement in NSCLC, and the choice of assay depends on criteria such as personnel requirements, analytical parameters (sensitivity, specificity), associated costs, and others [10]. Molecular alterations in ALK may be identified by fluorescent in situ hybridization (FISH), immunohistochemistry (IHC), real-time polymerase chain reaction (RT-PCR), and new molecular techniques as next-generation sequencing (NGS) and NanoString nCounter [11,12].
For some years, FISH has been the reference standard for detecting tumors carrying ALK rearrangement. However, growing evidence has shown that IHC testing is an efficient tool in the detection of ALK rearrangement, and confirmation of positive results by FISH is no longer needed [10,13].
The Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) have published common recommendations to guide biomarker testing in patients with advanced NSCLC according to current evidence. ALK rearrangement should be tested in all patients with adenocarcinoma or non-squamous carcinoma, and also in squamous cell carcinoma in patients aged < 50 years of age and/or with low or no tobacco use. According to guidelines for molecular diagnosis in advanced NSCLC patients, molecular testing of EGFR and BRAF mutations, ALK and ROS1 rearrangements and programmed death-ligand 1 (PD-L1) expression is considered mandatory [3,14].
The main objective of this analysis was to quantify the clinical and economic impact of the current molecular testing scenario of NSCLC patients in Spain, focusing on